Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2003-07-30
2009-08-11
Kwon, Brian-Yong S (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07572827
ABSTRACT:
The use of angelicin and its structural analogues for the preparation of a medicament for the therapeutic treatment of beta-thalassaemia is described. A structural analogue which is particularly preferred for this purpose is bergapten.
REFERENCES:
patent: 4021559 (1977-05-01), Giudiceli et al.
patent: 5569675 (1996-10-01), Rephaeili et al.
patent: 08231417 (1996-09-01), None
patent: WO 96 23495 (1996-08-01), None
patent: WO 96 40271 (1996-12-01), None
Lampronti et al., European Journal of Haematology, 2003, 71(3), 189-195.
X S Xu et al.: “Activation of Human Gamma-Globin Gene Expression via Triplex-forming Oligonucleotide (TFO)-directed mutations in the gamma-globin gene 5′ flanking region” GENE. Netherlands Jan. 25, 2000, vol. 242, No. 1-2, pp. 219-228, XP002260187, ISSN: 0378-1119.
Iiara et Lampronti et al: “Accumulation of gamma-globin mRNA in human erythroid cells treated with angelicin.” European Journal of Haematology, Denmark, Sep. 2003, vol. 71, No. 3, pp. 189-195, XP002260188, ISSN: 0902-4441.
D Rund et al.: “Pathophysiology of Alpha and Beta-Thalassemia: Therapeutic Implications” Seminars in Hematology, Philadelphia, PA, US, vol. 38, No. 4, Oct. 2001, p. s343-349, XP008015321, ISSN: 0037-1963.
MERK: “The Merk Index” 1999, Merk Research Laboratories, USA, XP002260189, p. 881, col. 1—p. 883, col. 2.
E.A. Rachmilewitz, et al., “Novel Treatment Options in the Severe β-Globin Disorders,”British Journal of Haematology, 1995, vol. 91, pp. 263-268.
J. Rochette, et al., “Fetal Hemoglobin Levels in Adults,”Blood Reviews, 1994, vol. 8, pp. 213-224.
Nicoletta Bianchi, et al., “Accumulation of γ-globin mRNA and induction of erythroid differentiation after treatment of human leukaemic K562 cells with tallismustine,”British Journal of Haematology, 2001, vol. 113, pp. 951-961.
George J. Dover, et al., “Increased Fetal Hemoglobin in Patients Receiving Sodium 4-phenylbutyrate,”The New England Journal of Medicine, vol. 327, No. 8, pp. 569-570, Aug. 20, 1992.
Tohru Ikuta, et al., “Cellular and Molecular Effects of a Pulse Butyrate Regimen and New Inducers of Globin Gene Expression and Hematopoiesis,”Annals New York Academy of Sciences, pp. 87-99, vol. 850, 1998.
Ling Dong Kong, et al., “Inhibition of Rat Brain Monoamine Oxidase Activities by Psoralen and Isopsoralen: Implications for the Treatment of Affective Disorders,”Pharmacology&Toxicology, 2001, vol. 88, pp. 75-80.
Luisa Mosti, et al., “Synthesis of angelicin heteranalogues: preliminary photobiological and pharmacological studies,”Il Farmaco, vol. 53, 1998, pp. 602-610.
Soroush Sardari, et al., “Synthesis and Antifungal Activity of Coumarins and Angular Furanocoumarins,”Bioorganic&Medicinal Chemistry, vol. 7, 1999, pp. 1933-1940.
Andreas E. Jakobs, et al., “A Convenient Synthesis of Thiopyrano [2,3-e]benzofuran: A New Sulfur Analogue of Angelicin,”J. Org. Chem., 1996, vol. 61, pp. 4842-4844.
Marzia Iester, et al., “Synthesis and Photobiological Properties of 3-acylangelicins, 3-alkoxycarbonylangelicins and Related Derivatives,”Il Farmaco, vol. 50, No. 10, pp. 669-678, 1995.
Emile Bisagni, et al., “Synthesis of psoralens and analogues,”J. Photochem. Photobiol. B: Biol., vol. 14, 1992, pp. 23-46.
Francesco Dall'Acqua, et al., “4′-Methylangelicins: New Potential Agents for the Photochemotherapy of Psoriasis,”J. Med. Chem., 1983, vol. 26, pp. 870-876.
Francesco Dall'Acqua, et al., “Methylangelicins: New Potential Agents for the Photochemotherapy of Psoriasis. Structure-Activity Study on the Dark and Photochemical Interactions with DNA,”J. Med. Chem., 1981, vol. 24, pp. 806-811.
Maria Teresa Conconi, et al., “Antiproliferative Activity and Phototoxicity of some Methyl Derivatives of 5-Methoxypsoralen and 5-Methoxyangelicin,”Pharmacology&Toxicology, 1998, vol. 82, pp. 193-198.
C. Marzano, et al., “DNA Damage and Cytotoxicity Induced in Mammalian Cells by a Tetramethylfuroquinolinone Derivative,”Environmental and Molecular Mutagenesis, vol. 29, pp. 256-264, 1997.
Franco Bordin, et al., “Angelicins, Angular Analogs of Psoralens: Chemistry, Photchemical, Photobiological and Phototherapeutic Properties,”Pharmac. Ther., vol. 52, pp. 331-363, 1991.
C. Nadine Backhouse, et al., “Active constituents isolated fromPsoralea glandulosaL. with anti-inflammatory and antipyretic activities,”Journal of Enthopharmacology, vol. 78, 2001, pp. 27-31.
Nicoletta Bianchi, et al., “Induction of Erythroid Differentiation of Human K562 Cells by Cisplatin Analogs,”Biochemical Pharmacology, vol. 60, pp. 31-40, 2000.
Nicoletta Bianchi, et al., “The DNA-binding drugs mithramycin and chromomycin are powerful inducers of erythroid differentiation of human K562 cells,”British Journal of Haematology, 1999, vol. 104, pp. 258-265.
E. Fibach, “Techniques for Studying Stimulation of Fetal Hemoglobin Production in Human Erythroid Cultures,”Hemoglobin, vol. 22, Nos. 5&6, pp. 445-458, 1998.
Eitan Fibach, et al., “Hydroxyurea Increases Fetal Hemoglobin in Cultured Erythroid Cells Derived From Normal Individuals and Patients With Sickle Cell Anemia or β-Thalassemia,”Blood, Vo. 81, No. 6, pp. 1630-1635, Mar. 15, 1993.
Christian A. Heid, et al., “Real Time Quantitative PCR,”Genome Research, vol. 6, pp. 986-994, 1996.
Ursula E.M. Gibson, et al., “A Novel Method for Real Time Quantitative RT-PCR,”Genome Research, vol. 6, pp. 995-1001, 1996.
Bianchi Nicoletta
Borgatti Monica
Gambari Roberto
Lampronti Ilaria
Associazione Veneta Per La Lotta Alla Talassemia
Kwon Brian-Yong S
Sughrue & Mion, PLLC
Universita' Degli Studi Di Ferrara
LandOfFree
Use of angelicin and of its structural analogues for the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of angelicin and of its structural analogues for the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of angelicin and of its structural analogues for the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4072274